Clinical trial
Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014
Name
REV-LUT-001
Description
Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.
Trial arms
Trial start
2012-08-01
Estimated PCD
2025-12-01
Trial end
2025-12-01
Status
Active (not recruiting)
Treatment
Lu-177 DOTA-TATE
The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.
Size
115
Primary endpoint
Efficacy data on subjects with neuroendocrine tumours (NET) treated with Lu-177 DOTA-TATE
Retrospective data January 2010 - April 30, 2014
Eligibility criteria
Subjects with neuroendocrine tumours who received Lu-177 DOTA-TATE treatment under SAP at the Cross Cancer Institute between January 2010 and April 30, 2014.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 115, 'type': 'ESTIMATED'}}
Updated at
2024-01-30
1 organization
1 product
2 indications
Organization
Alberta Health Services Cancer Control AlbertaProduct
Lu-177 DOTA-TATEIndication
Neuroendocrine TumorsIndication
Neuroendocrine Tumor